Browse > Article
http://dx.doi.org/10.3904/kjm.2012.83.4.520

Everolimus-Induced Interstitial Pneumonitis in a Patient with Metastatic Renal Cell Carcinoma: a Case Report  

Lee, So-Ra (Department of Internal Medicine, Dankook University College of Medicine)
Kim, Young-Min (Department of Internal Medicine, Dankook University College of Medicine)
Jung, Ji-Yun (Department of Internal Medicine, Dankook University College of Medicine)
Kim, Hyung-Joon (Department of Internal Medicine, Dankook University College of Medicine)
Kim, Doh-Hyung (Department of Internal Medicine, Dankook University College of Medicine)
Park, Keon-Woo (Department of Internal Medicine, Dankook University College of Medicine)
Lee, Soon-Il (Department of Internal Medicine, Dankook University College of Medicine)
Publication Information
The Korean Journal of Medicine / v.83, no.4, 2012 , pp. 520-524 More about this Journal
Abstract
Everolimus, an inhibitor of the mammalian target of rapamycin, is an active agent against metastatic renal cell carcinoma. Treatment with everolimus prolongs progression-free survival in patients with clear cell-type renal cell carcinoma that has progressed on vascular endothelial growth factor receptor tyrosine kinase inhibitors, such as sunitinib and/or sorafenib. Everolimus-induced interstitial pneumonitis is not rare and is sometimes fatal. Due to the potential for pulmonary toxicity due to everolimus, it is recommended that pulmonary complications be periodically evaluated. We report a case of everolimus-associated interstitial pneumonitis in a patient with metastatic renal cell carcinoma.
Keywords
Clear cell metastatic renal cell carcinoma; Everolimus; Interstitial pneumonitis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Shahani R, Kwan KG, Kapoor A. Safety and clinical efficacy of everolimus in the treatment of advanced renal cell carcinoma (RCC). Drug Healthc Patient Saf 2010;2:85-91.
2 Voss MH, Molina AM, Motzer RJ. mTOR inhibitors in advanced renal cell carcinoma. Hematol Oncol Clin North Am 2011;25:835-852.   DOI   ScienceOn
3 Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 2010;116:4256-4265.   DOI   ScienceOn
4 White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 2010;182: 396-403.   DOI   ScienceOn
5 Akata K, Yatera K, Ishimoto H, et al. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma. Intern Med 2011;50:3013-3017.   DOI
6 Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002;94: 1569-1575.   DOI   ScienceOn
7 Kondo K, Kim WY, Lechpammer M, Kaelin WG Jr. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.   DOI
8 Coppin C. Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib. Biologics 2010;4:91-101.
9 Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008;133: 528-538.   DOI   ScienceOn
10 Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer 2004;91(Suppl 2):S18-S23.